Phoenix PharmaLabs Awarded $2.7 Million Research Grant from DOD/USAMRAA for Further Development of Non-Addictive Opioid

SALT LAKE CITY–(BUSINESS WIRE)–#Phoenix–Phoenix PharmaLabs, a privately-held pre-clinical drug discovery company
dedicated to the development of potent, non-addictive treatment for pain
and treatments for addiction, has been awarded a $2.7 million grant from
the Department of Defense/US Army Medical Research Acquisition Activity.
The grant, for the project titled: “Pre-IND Development of PPL-103: A
potent Opioid Analgesic that is Safe, Non-Addicting, and Free of Other
Dangerous Opioid Side Effects,” will be used to complete these
pre-clinical studies. PPL-103 is the patented lead compound under
development at Phoenix. An IND filing with the FDA is required to
commence human clinical trials and the company expects to file this
within 18 months.

All opioids on the market today bind to the mu receptor in the brain and
then aggressively stimulate that receptor. The mu receptor produces
euphoria that leads to abuse and addiction. Phoenix’s drug, PPL-103, is
a patented analog that binds strongly to all three opioid receptors in
the brain (mu, kappa and delta) and then just partially stimulates each
of those receptors in a more balanced manner. This partial stimulation
derives potent analgesic benefit from all three receptors but is not
sufficiently strong to produce the serious opioid side-effects
associated with any single receptor. This results in a first-ever opiate
analgesic that appears to be non-addicting and free of all significant
dangerous side effects.

Further, in several published and unpublished in vivo studies
conducted to date, it has been shown that PPL-103 is:

  • An orally active potent pain killer (10x more potent than morphine)
  • Does not cause death from overdose (even when given at 350x dose)
  • Does not cause physical dependence or withdrawal
  • Does not cause constipation (even at 100X dose)
  • Has demonstrated potential as an opioid addiction therapy drug
    replacing currently used treatments that are themselves addictive
    opioids.

The U.S. Army Medical Research Acquisition Activity, 8720 Chandler
Street, Fort Detrick, MD 21702-5014 is the awarding and administering
office. This work was supported by the Assistant Secretary of Defense
for Health Affairs, through the FY 17 Broad Agency Announcement under
Award No. W8XWH-17-R-BAA1. Options, interpretations, conclusions and
recommendations are those of the author and are not necessarily endorsed
by the Department of Defense. In conducting research using animals, the
investigator(s) adheres to the laws of the United States and regulations
of the Department of Agriculture. In the conduct of research involving
hazardous organisms or toxins, the investigator adhered to the CDC-NIH
Guide for Biosafety in Microbiological and Biomedical Laboratories.

Phoenix recently announced a grant from NIH/NIDA to study PPL-103 for
its potential use as a treatment for cocaine addiction.

Phoenix PharmaLabs (www.phoenixpharmalabs.com)
is a privately held, preclinical drug discovery company focused on the
development and commercialization of new potent, non-addictive
treatments for pain and new therapies for the treatment of addiction.

Follow us on social media:

LinkedIn
* Twitter
* Facebook

Contacts

Bevlyn Consulting
Beverly Jedynak
312-943-1123
773-350-5793
(cell)
blj@bevlynconsulting.com

Laurel McBride real estate agent with Century 21 N and N Realtors with homes for sale in Logan Utah